Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data announced by its developer, Gri Bio. Data from the Phase 2a study (NCT06331624) broadly suggest that GRI-0621 is…
Starting the year with a vision of wellness and a plan to follow through
If you’re a regular reader of my column, you’ve likely heard me say before that transplant patients commit to a lifetime of medical surveillance. I was diagnosed with idiopathic pulmonary fibrosis (IPF) on the last day of January in 2017. Until then, I didn’t see my primary care…
Over the holidays, for the first time in a long while, my home was full of voices, laughter, movement, and the comfort of family. I hosted the gathering, something I hadn’t been able to do in years. For someone like me living with pulmonary fibrosis, hosting a holiday party…
Individuals with lingering signs of pulmonary fibrosis (PF) months after recovering from COVID-19 were found to be older and to have significantly lower levels than normal of beneficial gut bacteria, particularly Bifidobacterium and Blautia, a new study reports. In follow-up experiments, a mouse model of PF given supplements of…
When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in the early days of 2017, it seemed like my world moved in slow motion. Just a few months earlier, as my diagnostic journey began in the fall of 2016, my doctors sensed something was wrong, but no one could…
I had the opportunity to get away for a couple of days recently and went to the shore. As I looked out at the vastness of the ocean in the late afternoon sunlight, it occurred to me that this is what pulmonary fibrosis (PF) researchers face every day —…
The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring worsens over time. “Progressive pulmonary fibrosis is a life-threatening condition with a high unmet medical need. The U.S. approval…
Treatment with GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a clinical trial. The study (NCT06331624) met its primary goal, demonstrating no safety or tolerability concerns after 12 weeks of…
What is your earliest memory of the holidays? Whether you celebrate Hanukkah, Christmas, Kwanzaa, or another occasion, do you have memories of these holidays from your youth? How do they differ from more recent years? My earliest memories of Christmas are associated with gifts, such as acoustic and electric guitars,…
Your PF Community
Recent Posts
- Starting the year with a vision of wellness and a plan to follow through January 15, 2026
- New trial data show oral therapy alters immune pathways in adults with IPF January 14, 2026
- When you’re an IPF patient, the costs of care add up, but help is out there January 13, 2026
- Appearances can be deceptive for those living with pulmonary fibrosis January 13, 2026
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
